GTM is the only function you can't compare across your portfolio.
Finance compares. Ops compares. Talent compares. Ask how go-to-market is doing at eight companies and you get eight answers, none of them in the same units.
Andru measures GTM the same way at every company you hold, does the work to close the gaps it finds, and produces the evidence you take to the board.
No signup. No call.
The gap doesn't show up until it's expensive.
By the time weak GTM shows up in board metrics, the quarter is over. By the time it shows up in diligence, the deal is priced.
Revenue growth drives most of the value now. It's also the one input you're steering without instruments.
One instrument. Every company. Same units.
Andru scores every company on the same model: ICP clarity, pipeline efficiency, buying-committee coverage, concentration risk.
You stop reconciling eight board decks into one story. The comparison is already made.
The same model runs before you buy a company and before you sell one — GTM diligence pre-close, revenue-quality defence pre-exit.
It doesn't just find the gap. It closes it.
Andru rehearses your teams against the buying committee — including procurement, compliance, and the vendor manager who actually stalls the deal.
It builds the work: ICP analyses, battlecards, account plans, board decks. Then it ships them into your CRM, your inbox, and Slack.
No new headcount. No new vendors to manage.
Across the portfolio
Each company scored on the same model. Where growth is stalling, and whether it is the market or the motion.
Into the buying committee
What the CFO signs for. What the technical evaluator is afraid of. What procurement will stall on.
Toward the right investor
Which thesis a company actually fits, and which portfolio gap it fills.
Against the vendor
Real pricing flexibility, quarter-end incentives, and where the product falls short.
$ andru portfolio readiness
Scoring 8 companies on the same model...
⚠ Meridian Health — readiness down 11 pts this quarter
Pipeline is growing. Win rate is not.
Losing at the CFO, not the evaluator.
→ Business case is the gap, not the product.
⚠ Axon Logistics — concentration risk
Top 3 accounts are 61% of ARR.
→ Flag before diligence, not during.
$ andru rehearse --persona procurement
You are 20 minutes into a renewal negotiation.
"Your competitor quoted us 30% under. Walk me
through why I should not just take that."
✓ Debrief
Value articulation: held. You reframed on risk.
Gap: never asked what the 30% excluded.
An answer that survives the room.
Every number traces to its inputs: source, lead, deal, revenue.
Baselines are signed before the work starts, so attribution isn't an argument afterward.
What you share carries a cryptographic seal — so the number can be verified, not just trusted.
What you'd do instead.
A Big 4 assessment
$500K–$2M · 12–20 weeks
Excellent decks. The work stops when they leave.
Build it internally
Two to four people · $1M+ a year
It works, until the next vintage starts from zero.
Point tools
Clay, Gong, Clari
Strong inside one company. There is no cross-company layer.
Consultants leave. Tools don't compare.
Andru stays, and compares.
Who it's for.
PE operating partners
Comparable readiness across the holdings, without growing the team.
VC platform teams
One program across 30–80 founders, without becoming the bottleneck.
Building the company rather than backing it? Andru for founders — with prices shown.